Intravenous immunoglobulin (IVIG) replacement can sharply reduce severe infections in people with multiple myeloma, a cancer that progressively cripples the immune system’s ability to produce effective antibodies. The evidence is especially strong for patients receiving newer targeted therapies like bispecific antibodies, where one study found a roughly 90% drop in serious infections during periods of IVIG use. But the therapy is not one-size-fits-all, and how, when, and whether to start it involves a set of practical trade-offs that are still being sorted out.
Why Myeloma Leaves the Immune System Exposed
Multiple myeloma is a cancer of plasma cells, the immune cells responsible for manufacturing antibodies. As malignant plasma cells multiply in the bone marrow, they crowd out normal blood-cell production and flood the bloodstream with a single nonfunctional antibody (the monoclonal “paraprotein”) while suppressing the healthy B cells that would otherwise produce a diverse range of working antibodies. The result is hypogammaglobulinemia, meaning dangerously low levels of functional immunoglobulin G (IgG), the antibody class that does most of the heavy lifting against bacteria and viruses.1Frontiers in Immunology. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
The infection risk this creates is not subtle. A large Swedish study following more than 9,000 myeloma patients found they had a seven-fold higher risk of bacterial infections and a ten-fold higher risk of viral infections compared with matched controls. Within the first year of diagnosis, infections were the underlying cause in about one in five myeloma deaths.2PubMed Central. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients This vulnerability persists throughout the course of the disease and can worsen as treatments themselves further suppress immunity.
What IVIG Actually Does for Myeloma Patients
The core idea behind IVIG in myeloma is straightforward: if the patient’s own plasma cells can no longer produce functional antibodies, you supply them from outside. Pooled immunoglobulin collected from thousands of blood donors contains a broad library of antibodies against common pathogens. Infusing it restores some of the protective antibody coverage the patient has lost. Beyond simply replacing missing antibodies, immunoglobulin therapy also appears to have an immunomodulatory effect, strengthening other parts of the immune response that help fight infection.3PubMed Central. Immunoglobulin Replacement Therapy: Insights into Multiple Myeloma Management
The clinical payoff shows up most clearly in infection rates. An updated meta-analysis found that patients receiving immunoglobulin supplementation had a significantly lower cumulative incidence of severe infections compared with those who did not receive it, roughly 34% versus 56%.4PubMed. Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis That gap is meaningful in a population where a serious infection can derail cancer treatment, lead to hospitalization, and increase the risk of death.
The Bispecific Antibody Problem
The urgency around IVIG has intensified in recent years because of a new generation of myeloma treatments: bispecific antibodies (sometimes called “bispecifics” or BsAbs) that target a protein called BCMA on the surface of myeloma cells. Drugs like teclistamab and elranatamab are highly effective at killing myeloma cells, but they also destroy the normal plasma cells that share the BCMA target. The result is near-universal, often severe hypogammaglobulinemia. Among patients who responded to anti-BCMA bispecifics, essentially all developed critically low IgG levels.5Blood. Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
This makes bispecific antibody recipients a population where IVIG benefit is particularly dramatic. In one study, patients receiving IVIG during bispecific antibody treatment had a 90% lower rate of grade 3-5 infections (the kind that require hospitalization or are life-threatening) compared with periods when they were not receiving IVIG.6PubMed Central. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies A separate analysis of patients on teclistamab found that IVIG cut the annualized rate of severe infections by about two-thirds, from 0.93 to 0.33 per patient-year.7Blood Cancer Journal. Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab And in a cohort of 158 patients with relapsed or refractory myeloma on bispecifics, IVIG was independently associated with a 62% reduction in the risk of severe infections in multivariate analysis.8PubMed Central. Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Perhaps the most striking finding comes from a study looking beyond infection prevention alone. Patients who received IVIG as primary prophylaxis alongside BCMA-directed bispecific antibodies had significantly longer infection-free survival, but they also had better progression-free survival (a median of 15 versus 8 months) and better overall survival. On multivariate analysis, primary IVIG prophylaxis was independently associated with improved survival, with a hazard ratio of 0.37 for death.9Blood Cancer Journal. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma The likely explanation is that patients who avoid severe infections stay on their cancer therapy longer and with fewer dose delays, which means better tumor control.
How Bispecifics Compare to CAR-T Therapy on Infection Risk
CAR-T cell therapy is the other major BCMA-targeted approach in myeloma, and it creates its own immune suppression problems. After CAR-T, about 80% of patients develop hypogammaglobulinemia, and the antibody deficit often persists for more than a year. Low IgG before CAR-T is a strong predictor of both infection and death afterward.10PubMed Central. Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy
There is an important difference between the two approaches, though. During periods of treatment-emergent hypogammaglobulinemia, patients on bispecific antibodies had roughly twice the infection rate and a doubled risk of severe infection compared with CAR-T recipients.11Blood Cancer Journal. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma The reason is that bispecifics are given continuously (often every two weeks for months), so they keep wiping out new plasma cells as fast as the body tries to regenerate them. CAR-T is a one-time infusion; once the CAR-T cells wane, plasma cell recovery can begin. This distinction matters because it means IVIG may need to continue for the entire duration of bispecific therapy, and potentially beyond, while CAR-T patients may eventually recover enough antibody production to stop supplementation.
When to Start and How to Dose
One of the more contentious practical questions is timing. Some centers start IVIG prophylaxis only after a patient’s IgG falls below a specific threshold (say, 400 mg/dL), an approach called preemptive or IgG-guided treatment. Others argue for starting IVIG alongside bispecific antibody therapy from day one, regardless of what the IgG level looks like at that moment.
The evidence is tilting firmly toward the start-right-away camp. A study comparing preemptive immunoglobulin prophylaxis to no prophylaxis found a 66% reduction in all-grade infections and a 76% reduction in severe infections in the preemptive group, with infections also occurring earlier in patients who did not receive supplementation.12PubMed. Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies And a recent viewpoint in Blood Advances argued that waiting for IgG to drop below a threshold before starting replacement is neither scientifically sound nor clinically appropriate, partly because IgG measurements in myeloma patients can be unreliable. The monoclonal paraprotein can interfere with standard IgG assays, making levels look higher than they functionally are.13PubMed Central. Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels
Dosing typically follows a weight-based approach. Australian national guidelines, for instance, recommend a maintenance dose of 0.4 to 0.6 grams per kilogram of body weight every four weeks, adjusted to keep IgG trough levels at or above the lower limit of the normal range. In patients with chronic lung infections that are not adequately controlled, more frequent dosing or higher targets (up to 9 g/L trough) may be permitted, and total doses up to 1 g/kg per four-week period are allowed.14National Blood Authority. Acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation These are replacement-level doses, well below the high doses used for autoimmune diseases, and the infusions usually take a few hours in a clinic or infusion center.
Subcutaneous Immunoglobulin as an Alternative
Sitting in a clinic for an intravenous infusion every few weeks is a real burden for people already spending substantial time in medical settings for their cancer care. Subcutaneous immunoglobulin (SCIG) offers a different route: smaller, more frequent doses injected under the skin, often at home.
In a randomized trial of 46 myeloma patients with low IgG, those receiving subcutaneous immunoglobulin had significantly fewer severe infections per year. No patient in the SCIG arm developed sepsis, bacterial pneumonia, or acute sinusitis, compared with 24 cases of sepsis, 18 of pneumonia, and 5 of sinusitis in the control group. Side effects were limited to mild local skin reactions at the injection site. The patients also reported better quality of life and the approach was more cost-effective, largely because it reduced hospitalizations and antibiotic use.15Blood Cancer Journal. IgG replacement in multiple myeloma – Section: Subcutaneous IgG-RT (SCIG)
SCIG also produces more stable antibody levels between doses. Because it is given weekly rather than monthly, there is less of the “peak and trough” pattern seen with intravenous infusions, where IgG levels spike after infusion and gradually decline before the next one. A systematic review found that SCIG achieved trough levels averaging about 75 mg/dL higher than IVIG.15Blood Cancer Journal. IgG replacement in multiple myeloma – Section: Subcutaneous IgG-RT (SCIG) Patient satisfaction with subcutaneous administration tends to be high. In one study, over 96% of patients rated the convenience favorably, and more than 94% appreciated the option of self-administration and schedule flexibility. The lowest-rated aspect was the number of needle sticks per month, but even that was a complaint for fewer than 10% of patients.16Frontiers in Immunology. Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency
How IVIG Stacks Up Against Prophylactic Antibiotics
For decades, many centers used long-term prophylactic antibiotics instead of immunoglobulin replacement to prevent infections in patients with low antibody levels from blood cancers. Antibiotics are cheaper and easier to administer, but they carry their own drawbacks: they promote antibiotic-resistant bacteria, they do nothing against viral or fungal infections, and they can cause side effects like gut problems and drug interactions.
A head-to-head randomized trial comparing immunoglobulin replacement with prophylactic antibiotics in patients with hypogammaglobulinemia from blood cancers (including myeloma) found no clear winner. At 12 months, about 76% of patients on immunoglobulin and 71% on antibiotics were alive and still on their assigned treatment. Time to first major infection was slightly longer in the immunoglobulin arm (11.1 versus 9.7 months) but the difference was not statistically significant.17PubMed Central. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy The trial was small, though, and was not specifically powered to detect a difference in myeloma patients on bispecific antibodies, where the immune deficiency is far more severe than in the general blood-cancer population. Most experts now view antibiotics and immunoglobulin as complementary rather than either-or, particularly for high-risk patients.
Risks and Side Effects to Watch For
IVIG is generally well tolerated, but it is not risk-free. Infusion reactions are the most common issue: headaches, chills, nausea, and muscle aches during or shortly after the infusion. These are usually mild and can be managed by slowing the infusion rate or premedicating with acetaminophen and antihistamines. Switching from intravenous to subcutaneous delivery also helps patients who consistently react to IV infusions.18PubMed Central. Adverse Effects of Immunoglobulin Therapy
A more serious concern is blood clots. A study of patients with blood cancers receiving IVIG found a transiently elevated risk of arterial thromboembolic events on the day of infusion and the day after, with the risk declining over the rest of the treatment cycle. In absolute terms, the estimated increase in risk attributable to IVIG over a full year of treatment was small, about 0.7 percentage points above a baseline annual risk of 1.8%. The increase in venous clot risk was even smaller and not statistically significant.19PubMed Central. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy Still, since myeloma patients often have other clot risk factors (the disease itself, certain treatments, reduced mobility), this is something clinicians monitor.
Rare but recognized complications include kidney injury (especially with sucrose-containing IVIG formulations, which are now largely avoided), hemolytic anemia from antibodies in the pooled product that target the recipient’s red blood cells, and aseptic meningitis. These serious reactions are uncommon enough that for most patients, the infection-prevention benefit outweighs the risks by a wide margin.
The Evolving Guidelines Landscape
Despite the accumulating evidence, there is no single universally accepted guideline on when to start IVIG in myeloma. A systematic review and consensus statement in The Lancet Haematology concluded that optimal infection prevention in myeloma includes vaccination, antimicrobial prophylaxis, infection control, and immunoglobulin replacement in a subset of patients, but acknowledged the absence of universally accepted protocols. The field is moving fast, and practice varies considerably between cancer centers. Some start IVIG in every patient beginning bispecific antibody therapy; others still wait for recurrent infections or a measured IgG drop.
What is shifting the conversation is the growing recognition that in the bispecific antibody era, hypogammaglobulinemia is not a possible complication but a near-certainty, and that the infection consequences are severe enough to warrant proactive prevention. The data linking IVIG not just to fewer infections but to longer overall survival has raised the stakes. For patients on older myeloma therapies where immune suppression is less predictable, the calculus is different: monitoring IgG levels and starting replacement when they drop below a threshold may still be reasonable.
Practical Realities of Long-Term Immunoglobulin Therapy
For patients, the decision to start immunoglobulin replacement is not purely medical. Intravenous infusions typically require a clinic visit every three to four weeks, each lasting a few hours. That is on top of the time already spent on cancer treatment, blood work, and monitoring. The cost is substantial: IVIG is derived from human plasma and is one of the more expensive biological therapies, though coverage varies by country and insurance plan.
Subcutaneous administration eases some of this burden. Home-based self-injection, once patients are trained, eliminates the clinic visit and can be scheduled flexibly around work and daily life. About three-quarters of patients in one study were already managing their subcutaneous immunoglobulin at home.16Frontiers in Immunology. Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency The trade-off is more frequent injections, typically weekly, and the need to learn the injection technique.
Supply is another consideration. Immunoglobulin products depend on a limited supply of donated human plasma, and periodic shortages have affected availability in several countries. This is part of the reason clinicians think carefully about who benefits most from replacement therapy rather than giving it universally. Patients on bispecific antibodies with near-zero functional IgG are increasingly seen as a group where the benefit is clear enough to justify prioritizing supply. For patients with milder immune suppression and fewer infections, the decision is more nuanced and often involves trying prophylactic antibiotics first, reserving immunoglobulin for those who break through with infections despite antibiotic coverage.
One factor that does not get discussed enough is what happens when immunoglobulin therapy ends. For patients on bispecifics, stopping IVIG while still on treatment likely means a return to the pre-IVIG infection risk. For those who finish bispecific therapy, immune reconstitution can take months, and some patients remain hypogammaglobulinemic well beyond their last dose of cancer treatment. Deciding when it is safe to taper off requires serial IgG monitoring and clinical judgment, and there are no firm guidelines on the optimal stopping point.